CONTINUING LEGAL EDUCATION CREDIT SELF REPORTING ATTENDANCE AND EVALUATION FORM — TWENTY-FOURTH PHARMACEUTICAL AND MEDICAL DEVICE ETHICS AND COMPLIANCE CONGRESS

The Pharma/Device Congress is an approved Distance Learning Provider for PA MCLE. As such, the Congress will submit and pay for claimed CLE credits to PA MCLE for attorneys barred in Pennsylvania. For attorneys barred in other states, the Summit will post a record of their attendance at the Pharma Congress in the PA MCLE databases and will issue an Pharma Congress Certificate of Attendance that the attorney seeking CLE credits may use to self-report their participation to states. The Pharma Congress does not guarantee that states will accept the Certificate of Attendance.

As a pre-requisite to the submission of claimed CLE credits to PA MCLE for attorneys barred in Pennsylvania and the issuance of a Pharma Congress Certificate of Attendance, a Pharma Congress attorney attendee must:

- Pay a fee of $100 to the Pharma Congress @ **www.pharmacongress.com**, and
- Fully complete and execute this CONTINUING LEGAL EDUCATION CREDIT SELF REPORTING ATTENDANCE AND EVALUATION FORM FOR THE PHARMA CONGRESS. Payment must be made and the completed and executed form submitted via email to **cindyramirezghc@outlook.com** no later than **November 30, 2023.**

PERSONAL CONTACT INFORMATION

COMPLETE THE FOLLOWING:

NAME

SIGNATURE OF REGISTRANT - REQUIRED

JOB TITLE

STATE WHERE YOU PRACTICE

ADDRESS

CITY/STATE/ZIP

TELEPHONE

E-MAIL

PA BAR NUMBER IF FROM PA

NUMBER OF HOURS YOU PARTICIPATED

SELF REPORTING OF ATTENDANCE AT THE TWENTY-FOURTH PHARMA CONGRESS

Please mark those Pharma/Device Congress sessions below that you attended.

DAY I: WEDNESDAY, OCTOBER 25, 2023

SPECIAL INVITATION ONLY SESSION: CHIEF COMPLIANCE OFFICER ROUNDTABLE

- ☐ **What is the Role of Compliance in the Era of ESG?** — **1 hour**
- ☐ **The Rising Stakes of Data Governance and How Companies are Responding** — **1 hour**
- ☐ **A Fireside Chat on Whistleblowers with Kirsten Mayer, JD and Gregg Shapiro, JD** — **1 hour**
- ☐ **Open Forum: Q&A** — **.5 hour**

MINI SUMMITS GROUP I

- ☐ **MINI-SUMMIT 1: Compliance Primer and How to Make the Most of Your Time at the PCF Congress** — **.83 hour**
- ☐ **MINI-SUMMIT 2 : Data Analytic Strategies for Compliance** — **.83 hour**
- ☐ **MINI-SUMMIT 3: Insights from Medical Device Corporate Integrity Agreements** — **.83 hour**
- ☐ **MINI-SUMMIT 4: Update on Federal Government Pharmaceutical Price Negotiations** — **.83 hour**
- ☐ **MINI-SUMMIT 5: The Latest in Social Media Enforcements** — **.83 hour**

MINI SUMMITS GROUP II

- ☐ **MINI-SUMMIT 6: Government Enforcement Actions Piggy-Backing on Product Liability Litigation** — **.83 hour**
- ☐ **MINI-SUMMIT 7 : HCP Engagement: Business Needs Assessment, Contracting, and Activities Management** — **.83 hour**
- ☐ **MINI-SUMMIT 8: Preparing for Government Intervention in Drug Pricing** — **.83 hour**
- ☐ **MINI-SUMMIT 9: Alternative Funding Vendors: The Future and Options for Responding to New Challenges to Patient Support Programs** — **.83 hour**
- ☐ **MINI-SUMMIT 10: R&D and Clinical Trials Compliance Update** — **.83 hour**

MINI SUMMITS GROUP III

- ☐ MINI-SUMMIT 11: Proving the Value of Corporate Compliance — .83 hour
- ☐ MINI-SUMMIT 12 : Internal Investigations: Best Practices to Address Compliance Concerns and Reduce Risk — .83 hour
- ☐ MINI-SUMMIT 13: Insights and Actionable Deliverables in Response to the DOJ Self-Disclosure Policy — .83 hour
- ☐ MINI-SUMMIT 14: Compliance Considerations for Market Access Initiatives — .83 hour
- ☐ MINI-SUMMIT 15: Data Analytics to Monitor Payments to HCPs, HCOs, Distributors, and Other Third Parties — .83 hour

MINI SUMMITS GROUP IV

- ☐ MINI-SUMMIT 16: All Things Patients — .83 hour
- ☐ MINI-SUMMIT 17 : Evolving Risks in Medical Affairs — .83 hour
- ☐ MINI-SUMMIT 18: Contemporary Trends in Fair Market Value — .83 hour
- ☐ MINI-SUMMIT 19: Risk & Ethics Perspective of Artificial Intelligence — .83 hour
- ☐ MINI-SUMMIT 20: Drug Pricing — Considerations around Price Controls, Negotiation, and Access — .83 hour

LUNCHEON MINI SUMMITS GROUP V

- ☐ MINI-SUMMIT 21: The Role of Fair Market Value in Pharma and Medical Device Compliance Programs — .83 hour
- ☐ MINI-SUMMIT 22 : Responsibly Harnessing the Power of AI — .83 hour
- ☐ MINI-SUMMIT 23: Is the "No Patient Left Behind" Approach to Patient Support Programs Viable? — .83 hour
- ☐ MINI-SUMMIT 24: Assessing Compliance Priorities: Considerations for Conducting an Effective and Collaborative Compliance Risk Assessment — .83 hour

OPENING PLENARY SESSION

- ☐ Keynote Fireside Chat with Geoff S. Martha, Chairman and Chief Executive Officer, Medtronic — .5 hour
- ☐ Keynote: OIG Update — .75 hour
- ☐ US DOJ Keynote — .5 hour
- ☐ Strategic, Behavioral Compliance, and Economic Considerations Regarding DOJ's Pilot Program — .5 hour
- ☐ Prosecution and Enforcement Actions Update — .75 hour
- ☐ Annual Chief Compliance Officer Fireside Chat — 1 hour

DAY II: THURSDAY, OCTOBER 26, 2023

BREAKFAST MINI SUMMITS GROUP VI

- ☐ MINI-SUMMIT 25: Sanctions — Compliance Monitoring Approaches and Tools — .83 hour
- ☐ MINI-SUMMIT 26 : A Fireside Chat with Jim Sheehan, JD — .83 hour
- ☐ MINI-SUMMIT 27: Key Learnings from CMS Audits of Open Payments — .83 hour
- ☐ MINI-SUMMIT 28: New Levels of Transparency and Governance Across the Device and Pharma Ecosystems — .83 hour

MINI SUMMITS GROUP VII

- ☐ MINI-SUMMIT 29: Hiring and Developing Compliance Leaders — .83 hour
- ☐ MINI-SUMMIT 30 : Privacy & Data Protection: Changes in Laws and the Impact on Our Industry — .83 hour
- ☐ MINI-SUMMIT 31: Annual FCPA Update — .83 hour
- ☐ MINI-SUMMIT 32: Developing an Effective AI Governance Model: What you Need to Know — .83 hour
- ☐ MINI-SUMMIT 33: Navigating M&A of FDA-Regulated Companies — .83 hour
- ☐ MINI-SUMMIT 34: Enterprise Communications Monitoring and the Recent DOJ Guidance — .83 hour
- ☐ MINI-SUMMIT 35: DEI Training: Why It Matters and How to Do It? — .83 hour

MINI SUMMITS GROUP VIII

- ☐ MINI-SUMMIT 36: Outsourced Compliance Programs: How to Make them Work? — .83 hour
- ☐ MINI-SUMMIT 37 : Fostering a Speak Up Culture at Your Organization — .83 hour
- ☐ MINI-SUMMIT 38: AI — Art of the Possible — .83 hour
- ☐ MINI-SUMMIT 39: Third Party Risk Management: Onboarding Diligence, Oversight and Exercising Audit Rights — .83 hour
- ☐ MINI-SUMMIT 40: Global Aspects and Challenges of FCPA/Compliance Investigations — .83 hour
- ☐ MINI-SUMMIT 41: Compliance Considerations for Small and Emerging Companies — .83 hour
- ☐ MINI-SUMMIT 42: Legal Risks Around Digital Health Technology — .83 hour

MINI SUMMITS GROUP IX

- ☐ **MINI-SUMMIT 43:** Global Ethics and Compliance: Evolution of Legislation — .83 hour
- ☐ **MINI-SUMMIT 44:** DOJ Agreements, Dual Reporting and the Role of the Compliance Officer — .83 hour
- ☐ **MINI-SUMMIT 45:** Compliance in Life Science: Unleashing AI's Potential — .83 hour
- ☐ **MINI-SUMMIT 46:** Engaging Your Board Effectively in an Era of Heightened Scrutiny and Enforcement Risk — .83 hour
- ☐ **MINI-SUMMIT 47:** Pixels and Privacy: Navigating the Litigation and Enforcement Landscape of Website and Mobile App Privacy — .83 hour
- ☐ **MINI-SUMMIT 48 :** The Modern Investigation: Current Best Practices for Investigation — .83 hour
- ☐ **MINI-SUMMIT 49:** Using Behavioral Compliance to Improve Your Compliance Program — Practical Implementation Suggestions — .83 hour

MINI SUMMITS GROUP X

- ☐ **MINI-SUMMIT 50:** Global Ethics and Compliance: ESG Governance — .83 hour
- ☐ **MINI-SUMMIT 51:** Navigating Compliance Challenges: Real-World Case Studies and Solutions — .83 hour
- ☐ **MINI-SUMMIT 52 :** Compliance Considerations for Rare Disease — .83 hour
- ☐ **MINI-SUMMIT 53:** What Do Health Equity Initiatives Mean for Compliance? — .83 hour
- ☐ **MINI-SUMMIT 54:** Fireside Chat: Reflections on the Role of the False Claims Act Liability over the past 50 Years into a Major Force in the Regulation of the Pharmaceutical and Medical Device Industries — .83 hour
- ☐ **MINI-SUMMIT 55:** Evolving Board of Directors and Compliance Committees Oversight Obligations — .83 hour
- ☐ **MINI-SUMMIT 56:** Comedy & Compliance — Shifting Culture & Building Trust with Entertainment — .83 hour

LUNCHEON MINI SUMMITS GROUP XI

- ☐ **MINI-SUMMIT 57:** Recent Developments in DOJ and FTC Enforcement Actions — .83 hour
- ☐ **MINI-SUMMIT 58:** Building Fearlessness into Organizations — .83 hour
- ☐ **MINI-SUMMIT 59:** Compliance Monitoring — Operational Insights and Lessons Learned — .83 hour
- ☐ **MINI-SUMMIT 60:** Old Concepts New Risks: Trends in Medical Education Support Compliance — .83 hour

CLOSING PLENARY SESSION

- ☐ Keynote Fireside Chat with Richard Simkin, Chief Commercial Officer, Indivior — .5 hour
- ☐ The Future Chief Compliance Officer — .75 hour
- ☐ FDA Keynote — .5 hour
- ☐ Updates from AdvaMed and PhRMA — .5 hour
- ☐ Strategic Resource Management for Optimized Compliance — .5 hour
- ☐ What's Next in Pharma: Confronting a Challenging Macroeconomic Environment with Innovation — .5 hour

DAY III: FRIDAY, OCTOBER 27, 2023

INDUSTRY-ONLY COMPLIANCE BEST PRACTICES THINK TANK

- ☐ AI, ChatGPT, and Machine Learning — What Every Compliance Professional Needs to Know! **1 hour**
- ☐ Key Takeaway Table Discussions **.25 hour**
- ☐ Best Practice Sharing: Latest DOJ Guidances: How Is Your Company Preparing? **.5 hour**
- ☐ How to be a Wildly Effective Compliance Officer? **1 hour**
- ☐ Key Takeaway Table Discussions **.25 hour**
- ☐ Open Forum — Q&A and Best Practice Sharing **.5 hour**

WEDNESDAY, NOVEMBER 15, 2023

VIRTUAL GLOBAL PHARMA & MEDICAL DEVICE ETHICS & COMPLIANCE DAY

- ☐ Keynote Address: Challenges in Developing a Truly Global Ethics and Compliance Program **.5 hour**
- ☐ EU, CEE and MEA Ethics and Compliance Developments Update Roundtable **1 hour**
- ☐ Asia Pac Ethics and Compliance Developments Update Roundtable **1 hour**
- ☐ LatAm Ethics and Compliance Developments Update Roundtable **1 hour**
- ☐ A Fireside Chat on Navigating the Cultural Challenges in Global Compliance Programs with Hui Chen, JD **.5 hour**

EVALUATION FORM FOR THE PHARMA CONGRESS

You must also complete the following Pharma/Device Congress evaluation form:

	Failed to Meet Expectations	Needs Improvement	Met Expectations	Exceded Expectations	Excellent
Overall Quality	☐	☐	☐	☐	☐
Powerpoints	☐	☐	☐	☐	☐
Speakers	☐	☐	☐	☐	☐
Ease of Use	☐	☐	☐	☐	☐

EXECUTION OF THE CONTINUING LEGAL EDUCATION CREDIT SELF REPORTING ATTENDANCE AND EVALUATION FORM FOR THE PHARMA CONGRESS

By executing this self-reporting form, the attorney hereby warrants that the information provided herein is complete, true and correct.

Executed by: _____ **Date:** _____

Payment must be made and the completed and executed form submitted via email to **cindyramirezghc@outlook.com** no later than **November 30, 2023.**